AYTU (Aytu BioPharma) ROCE %: -38.26% (As of Mar. 2026)


AYTU Aytu BioPharma Inc AYTU
40 GF Score
Price $2.21
GF Value $0.84
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Aytu BioPharma ROCE %?

Aytu BioPharma AYTU -0.91% 40 ROCE % is -38.26% as of Mar. 2026. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.84 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aytu BioPharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -38.26%.

Aytu BioPharma  (NAS:AYTU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aytu BioPharma ROCE % Related Terms

Aytu BioPharma ROCE % Historical Data

* Premium members only.

The historical data trend for Aytu BioPharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma ROCE % Chart

Aytu BioPharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.24 -31.47 -17.19 -8.63 -17.17

Aytu BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.72 -130.62 16.53 -69.47 -38.26
AYTU
40GF Score
Aytu BioPharma Inc AYTU
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aytu BioPharma ROCE % Calculation

Aytu BioPharma's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-10.042/( ( (118.095 - 62.228) + (124.177 - 63.064) )/ 2 )
=-10.042/( (55.867+61.113)/ 2 )
=-10.042/58.49
=-17.17 %

Aytu BioPharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-20.688/( ( (122 - 65.563) + (111.689 - 59.972) )/ 2 )
=-20.688/( ( 56.437 + 51.717 )/ 2 )
=-20.688/54.077
=-38.26 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -38.26% mean?
Aytu BioPharma (AYTU) has a ROCE % of -38.26% as of Mar. 2026.
Is Aytu BioPharma's ROCE % too high?
Aytu BioPharma's current ROCE % is -38.26%. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's ROCE % compare to TXMD and KAYS?
Aytu BioPharma's ROCE % of -38.26% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current ROCE % is -38.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.84, compared to a current price of $2.21 — trading 163.1% above its estimated fair value. The current ROCE % is -38.26%. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current ROCE % is -38.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aytu BioPharma (AYTU) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.21 is trading 163.1% above its estimated GF Value™ of $0.84. GuruFocus considers Aytu BioPharma to be Significantly Overvalued.

Key valuation signals for AYTU:

  • ROCE %: -38.26%
  • GF Value™: $0.84 vs. price of $2.21 (163.1% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aytu BioPharma Business Description

Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score

Get the complete analysis for AYTU

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.21
Price
$0.84
GF Value